BLOO7 schreef op 8 augustus 2018 12:10:
[...]
Als de uitvindster zegt dat filgotinib beter is dan geloof ik haar.
Punt.
Dat is vertrouwen.
Stukje over Abbvie. We continue to monitor the progress of Filgotinib, a competing product that AbbVie decided to pass on to instead focus on developing Upa. Thus far, in Phase 2 clinical trials, Filgotinib has posted the cleanest safety profile with the least effect on platelets of the class, thus setting up a potential key differentiator with Upa and Olumiant. If Filgotinib can make it through Phase 3 trials (due out in 2019) with a notable absence of VTEs, we view this as an additional nail in the coffin of the UPA Jak-1 dominance thesis. This won’t be good for AbbVie.
seekingalpha.com/amp/article/4195706-...En ik begrijp dat zij schrik hebben.